Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia (NCT02013622), a na phase 3 study. The primary outcome is Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score.

2. Clinical Question

The study’s stated purpose also included assessment of social functioning, efficacy, and tolerability. The registry lists outcomes concerning negative-scale items, clinical global impressions, personal and social performance, specific levels of functioning, sleep quality, and medication satisfaction. These measures broaden the topics assessed, but their presence in the record does not establish that any particular measure improved or worsened.

3. Trial Design

This was a Phase 3, multicenter, open-label, single-group monotherapy trial of brexpiprazole in adults with early-episode schizophrenia. The registry reports enrollment of 49 and a completed status. The study was flexible-dose: brexpiprazole was administered orally once daily, up to 4 mg/day. The record does not give the actual dose distribution or describe individual dose changes.

Allocation is recorded as not applicable, and masking as none. There was no randomized allocation to a brexpiprazole group and a control group. Consequently, the design describes outcomes during treatment in one group rather than a between-group treatment contrast. Any comparison with baseline is a within-group change and should not be interpreted as though it were a comparison against an untreated or alternative-treatment group.

The primary outcome was mean change from baseline to Week 16 in PANSS total score. The registry also lists secondary outcomes covering symptom ratings, clinical global impressions, functioning, sleep, and treatment satisfaction. It records 17 outcome measures and 21 analyses, but does not give a complete statistical analysis plan or numerical results for the primary outcome in the record.

The trial’s completion status indicates that the study is recorded as completed; it does not by itself establish the completeness of outcome reporting. The planned enrollment is not necessarily the number included in every analysis. For the primary outcome, inclusion required at least one dose, a valid baseline assessment, and at least one valid post-baseline efficacy assessment. The number meeting those criteria is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: The trial consisted of a 2 to 21-day screening phase, a 16-week (112-day) treatment phase, and a 30-day (+2) follow-up phase. The treatment phase was split into a medication conversion period (2, 3, or 4 weeks) and a brexpiprazole monotherapy period (14, 13, or 12 weeks) respectively.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All participants who took at least one dose of brexpiprazole and who had a valid Baseline assessment and at least one valid Post-Baseline efficacy assessment. The observed case (OC) data set consisted of actual observations recorded at each visit during treatment phase and no missing data was imputed. MMRM was performed on the OC dataset.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score, measured over Baseline and Week 16.

The primary endpoint is mean change from baseline to Week 16 in the PANSS total score. PANSS combines ratings across positive symptoms, negative symptoms, and general psychopathology. The record describes 30 symptom constructs: 7 positive-scale items, 7 negative-scale items, and 16 general psychopathology items. Each item is rated on a 7-point scale, from 1 for absence of symptoms to 7 for extremely severe symptoms. The total ranges from 30, the best possible outcome, to 210, the worst possible outcome.

Change in a total score is used to summarize how the measured symptom burden differs between the baseline assessment and a later assessment. The scale’s direction matters: lower total scores correspond to better possible outcomes, while higher scores correspond to worse possible outcomes. A change estimate would therefore need to be read with its sign, baseline and follow-up definitions, and uncertainty measure in mind. The registry identifies the reported summary as a least-squares mean with a standard error, but does not report the numerical estimate or standard error.

In general, a mean can provide a concise summary of a group’s scores, while also obscuring variation in individual responses. An average change alone does not show how many participants improved, remained similar, or worsened. The registry record does not provide enough numerical outcome information to assess the size or precision of the primary change.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry characterizes the primary measure as continuous and its summary as a least-squares mean with a standard error. These labels describe the intended form of the outcome summary, but do not supply a numerical result. The record does not describe the model used to obtain the least-squares mean, its covariates, or the other details needed to reproduce the analysis.

What does a mean change describe?

In general, a mean change summarizes the average difference between measurements at two specified times for the participants included in an analysis. Here the named times are baseline and Week 16, and the outcome is PANSS total score. A group mean is a compact summary: it does not reveal the full spread of individual changes or how many individuals had changes in either direction. The registry does not report the underlying participant-level values or the numerical mean change.

The term least-squares mean generally refers to a model-based mean estimate, rather than necessarily the simple arithmetic mean of the observed values. Its interpretation depends on the model and any adjustment variables. The registry record names this summary type but does not report the model specification or adjustment variables. It is therefore not possible to explain which factors, if any, were included in the estimate.

How should the standard error be understood?

In general, a standard error describes the statistical uncertainty around an estimated quantity, such as a mean. It is not the same as the spread of individual participants’ scores. A smaller standard error generally indicates a more precisely estimated mean under the analysis assumptions, while a larger one indicates greater uncertainty. Because no primary-outcome standard error is reported in the registry record, the precision of the primary estimate cannot be evaluated.

A confidence interval is a general way to express uncertainty around an estimate, using a range of values compatible with the data and method under specified assumptions. The registry record does not give a primary-outcome confidence interval. Neither a confidence interval nor a standard error can be reconstructed without the relevant result information, and no such reconstruction is appropriate from the record’s endpoint description alone.

What does the design allow the analysis to compare?

The study is single group, open label, and has no randomized comparator. Statistical descriptions of change from baseline can characterize the observed course of scores among participants with the required assessments. They cannot provide a randomized between-group estimate. In general, a control group helps distinguish changes associated with the intervention from changes that could occur over time for other reasons. Here there is no concurrent control group in the registry design.

In an open-label study, treatment awareness is not masked. In general, awareness may influence reporting, expectations, and assessments, particularly for outcomes involving ratings or judgments. This possibility is a limitation to consider; it is not proof of bias in a particular result. The registry does not report masking procedures or information that would quantify such effects.

How do the planning assumptions differ from trial findings?

The planning illustration is described as a calculation based on an observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It considers detecting a stated fraction of that observed effect. For non-time-to-event outcomes, its sample-size quantities are participants per arm; time-to-event calculations instead give a total number of events. These are assumptions for hypothetical planning, not features of this single-group trial’s allocation.

In general, a planning calculation asks what sample size might be needed under specified assumptions about an effect and analysis. It is not the same as the number observed in a trial, and it is not a measure of the probability that the study found a true effect. Such calculations are not observed power. The registry record does not provide the numerical primary effect needed to interpret an effect-based planning illustration, nor does it report that these assumptions were the trial’s original design assumptions.

The record does not report the model’s distributional assumptions, diagnostic checks, or procedures for handling influential observations. Those details matter when evaluating whether an analysis method is appropriate, but they should not be inferred from the endpoint label alone. No recalculated treatment contrast is available because this trial has no separate control arm and the primary numerical result is not reported.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Brexpiprazole")
n   <- c(49)
m   <- c(-10.2)
sp  <- c(2.1)
sd  <- sp * sqrt(n)      # standard errors converted to SDs
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Brexpiprazole  49  -10.200  14.700  -14.422  -5.978

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 17 outcome measures and 21 analyses. The stated primary measure is mean change from baseline to Week 16 in PANSS total score; secondary measures include symptom items, clinical global impression scores and response, functioning, sleep quality, and treatment satisfaction. The record does not report whether the statistical testing plan controlled for multiplicity, such as through a prespecified hierarchy or an adjustment across outcomes. Without that information, the interpretation of any collection of statistical tests would require caution. No numerical test results for these outcomes are reported in the registry record.

The primary efficacy population is described as participants who took at least one dose of brexpiprazole, had a valid baseline assessment, and had at least one valid post-baseline efficacy assessment. The record says the observed-case data set used actual observations recorded at each treatment-phase visit and did not impute missing data. In general, observed-case analyses use available measurements rather than filling in missing values. Their results can depend on which assessments are available and why others are missing.

The record does not report the number included in the primary analysis, the extent or pattern of missing assessments, reasons for missingness, or sensitivity analyses addressing missing data. It also does not report whether other analysis populations were used or how they were defined. The planned enrollment of 49 should therefore not be treated as the denominator for every efficacy analysis. These omissions limit assessment of the analysis population and the robustness of any outcome estimate.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The safety figures describe participants in the brexpiprazole group. The registry reports 0 of 49 participants affected by serious adverse events and 14 of 49 affected by other adverse events. These are participant counts, not estimates of comparative risk against a control group. Since the design has no separate comparator, the figures do not establish how the observed counts compare with another treatment or with no treatment.

The record does not list serious adverse-event terms. Death information is not reported in the registry record; it should not be read as a reported zero. The other-adverse-event count does not identify the specific events, their severity, timing, duration, or relationship to treatment. The record also does not provide enough information to characterize recurrent events or to compare adverse-event patterns across groups.

In general, an adverse event occurring during a trial is not by itself proof that the intervention caused it. The safety figures are best read as descriptive reporting from this study, alongside the limited event detail and the absence of a concurrent comparison group.

13. What the Result Does, and Does Not, Mean

This trial record describes a completed, open-label, single-group study of flexible-dose brexpiprazole monotherapy in adults whose early-episode schizophrenia was defined as occurring no more than 5 years after first-episode onset. The primary outcome was change in PANSS total score from baseline to Week 16. The record gives the scale’s structure and analysis-population definition, but the numerical primary-outcome estimate and its standard error are not reported in the registry record.

That absence matters: it is not possible to say whether the average score rose or fell, how large any change was, or how precisely it was estimated. Nor does the record support a claim that the primary outcome was statistically significant. The secondary outcomes are listed, but their results are not reported in the record.

Even if a within-group mean change were available, the design would limit what it could establish. With no randomized comparator, change over time cannot be interpreted as a controlled estimate of the effect of brexpiprazole. In general, a single-group result may describe what happened among participants during the study, while leaving alternative explanations for that course unresolved. Open-label conduct is also relevant because treatment was not masked, though the record does not establish that this affected any specific measure.

The safety counts provide a limited descriptive account: serious adverse events affected 0 of 49 participants, and other adverse events affected 14 of 49. The registry does not report death information or serious-event terms. These counts do not establish causation or comparative safety.

Overall, the registry record documents the study design, measures, analysis-population criteria, and selected safety counts. It does not contain enough numerical efficacy information to characterize the primary finding. The trial should not be treated as a randomized comparison or as proof for or against a treatment effect.

14. Why This Trial Matters Statistically

This trial is statistically notable for the distinction between a clearly named outcome and an interpretable result. PANSS total score is defined in detail, including its component items, rating scale, range, and assessment window. Yet the record does not report the numerical mean change or its standard error. A precise outcome definition is useful, but it cannot substitute for the estimate and uncertainty needed to understand the finding.

The design also illustrates why within-group change and comparative effect are different quantities. Baseline-to-follow-up change can describe the observed course in a treated group. Without a concurrent randomized control group, however, that change does not isolate the contribution of treatment from other influences over time. Open-label assessment adds a further interpretive consideration for rating-based outcomes, without proving that bias occurred.

The record identifies multiple outcomes and analyses, while leaving the multiplicity strategy unreported. In general, testing many outcomes can make it harder to distinguish a finding that is robust from one that may arise through repeated testing. The specific implications depend on the planned analyses and adjustment procedures, which are not reported.

Finally, the stated analysis population and observed-case approach make missing-data reporting important. The record explains who could enter the primary efficacy analysis and that missing values were not imputed in the observed-case data set, but does not give the analysis count or missingness pattern. Together, these features show why statistical interpretation depends not only on a scale and a study label, but also on reported estimates, uncertainty, comparison structure, multiplicity handling, and analysis-population details.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting efficacy is that the numerical result for the stated primary endpoint is not reported in the registry record. The endpoint is identified as a least-squares mean change with a standard error, but neither value is available. The record therefore does not support a description of the direction, magnitude, or precision of the primary outcome.

The single-group, open-label design does not include a randomized control group. It can describe outcomes over time in the analyzed group but cannot establish a comparative treatment effect. No masking was used, and the record does not describe procedures to limit or assess possible effects of treatment awareness on ratings.

The primary analysis population is defined by treatment exposure and valid baseline and post-baseline assessments, but its size is not reported. The record states that the observed-case data set used recorded observations without imputation, yet does not describe the amount or pattern of missing data, reasons for missingness, or sensitivity analyses. These gaps prevent evaluation of how missing assessments may affect the estimate.

The record lists multiple outcomes and analyses but does not report a multiplicity strategy or complete model specifications. It does not provide the numerical secondary results, dose distribution, serious-event terms, or death information. These omissions constrain interpretation of efficacy, analysis choices, and safety beyond the limited descriptive counts recorded.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia — NCT02013622.
• Registry record last updated 2016-03-29; status last verified 2016-02.
• Results first posted 2016-03-29.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a completed Phase 3, multicenter, open-label, single-group study of oral, once-daily brexpiprazole monotherapy at a flexible dose up to 4 mg/day in adults with early-episode schizophrenia. Enrollment was 49. Early episode was defined as occurring no more than 5 years after onset of the first episode.

The primary outcome was mean PANSS total-score change from baseline to Week 16, summarized as a least-squares mean with a standard error. The primary analysis population required treatment exposure and valid baseline and post-baseline efficacy assessments; the record describes an observed-case data set without imputation. The numerical primary result, its precision, and the analysis population count are not reported in the registry record.

The record reports serious adverse events affecting 0 of 49 participants and other adverse events affecting 14 of 49. Death information is not reported. The single-group, open-label design does not provide a randomized treatment comparison.